SecSonar.com

Liquidia Corporation (LQDA)

Liquidia Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Liquidia Corporation (LQDA) is a Biotechnology company based in US with a market capitalization of $5.5B. Revenue grew 1031.2% year-over-year and free cash flow was negative at -$40M. This page tracks LQDA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 170 employees · IPO Jul 26, 2018

Valuation

Valuation & price

$56.93 · as of May 17, 2026 · -28.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

121.98

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$78.93$45.69$12.45Jul 25Dec 25Jul 26Jul 7, 25$12.45Jul 9, 25$13.48Jul 11, 25$14.09Jul 15, 25$14.51Jul 17, 25$14.60Jul 21, 25$15.10Jul 23, 25$17.75Jul 25, 25$19.60Jul 29, 25$19.26Jul 31, 25$18.69Aug 4, 25$19.48Aug 6, 25$20.31Aug 11, 25$21.20Aug 13, 25$25.20Aug 15, 25$25.95Aug 19, 25$27.11Aug 21, 25$27.30Aug 25, 25$26.25Aug 27, 25$28.00Aug 29, 25$27.68Sep 3, 25$29.22Sep 5, 25$28.85Sep 9, 25$27.80Sep 11, 25$27.00Sep 16, 25$26.03Sep 18, 25$24.67Sep 22, 25$22.90Sep 24, 25$21.94Sep 26, 25$21.80Sep 30, 25$22.74Oct 2, 25$21.90Oct 6, 25$22.86Oct 8, 25$24.08Oct 10, 25$23.19Oct 14, 25$22.77Oct 16, 25$23.18Oct 21, 25$23.59Oct 23, 25$22.02Oct 27, 25$22.76Oct 29, 25$22.45Oct 31, 25$24.36Nov 4, 25$27.91Nov 6, 25$25.60Nov 10, 25$27.26Nov 12, 25$28.31Nov 14, 25$28.04Nov 18, 25$30.20Nov 20, 25$28.56Nov 25, 25$32.26Nov 28, 25$32.63Dec 2, 25$30.79Dec 4, 25$33.92Dec 8, 25$35.01Dec 10, 25$32.68Dec 12, 25$33.38Dec 16, 25$35.26Dec 18, 25$33.67Dec 22, 25$35.78Dec 24, 25$35.79Dec 29, 25$34.75Jan 2, 26$31.40Jan 6, 26$30.72Jan 8, 26$31.76Jan 12, 26$36.60Jan 14, 26$39.99Jan 16, 26$37.93Jan 21, 26$39.99Jan 23, 26$40.59Jan 27, 26$42.48Jan 29, 26$43.06Feb 2, 26$44.21Feb 4, 26$44.43Feb 9, 26$42.40Feb 11, 26$40.17Feb 13, 26$38.20Feb 18, 26$34.96Feb 20, 26$33.59Feb 24, 26$33.57Feb 26, 26$30.79Mar 2, 26$30.94Mar 4, 26$34.38Mar 6, 26$36.03Mar 10, 26$38.83Mar 12, 26$37.58Mar 17, 26$36.86Mar 19, 26$37.36Mar 23, 26$35.50Mar 25, 26$36.61Mar 27, 26$35.03Mar 31, 26$37.74Apr 2, 26$37.68Apr 7, 26$37.36Apr 9, 26$40.32Apr 13, 26$38.85Apr 15, 26$40.12Apr 17, 26$39.47Apr 22, 26$37.06Apr 24, 26$37.31Apr 28, 26$37.65Apr 30, 26$39.21May 4, 26$38.48May 6, 26$42.14May 8, 26$42.30May 12, 26$56.60May 14, 26$59.30May 18, 26$56.97May 20, 26$61.77May 22, 26$60.98May 28, 26$62.03Jun 1, 26$58.75Jun 3, 26$55.69Jun 5, 26$61.85Jun 9, 26$64.01Jun 11, 26$71.63Jun 15, 26$71.80Jun 17, 26$68.65Jun 22, 26$75.49Jun 24, 26$75.54Jun 26, 26$78.17Jul 2, 26$78.93
$12.4552-week range$79.73
Loading valuation history…

Fundamentals

Key fundamentals

$5.5B

Market cap

1031.2%

Revenue growth (YoY)

91.6%

Gross margin

-$40M

Free cash flow (USD)

$7.2M

Net debt

9.3%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$13.2MFY 2017$7.3MFY 2018$2.7MFY 2019$8.1MFY 2020$739.6KFY 2021$12.9MFY 2022$15.9MFY 2023$17.5MFY 2024$14.0MFY 2025$158.3M
$13.2M$158.3M

Free cash flow by year

2016 → 2025

FY 2016$-16.8MFY 2017$-26.8MFY 2018$-32.7MFY 2019$-50.1MFY 2020$-54.9MFY 2021$-34.1MFY 2022$-29.2MFY 2023$-42.9MFY 2024$-98.4MFY 2025$-40.0M
-$16.8M-$40M

Gross margin by year

2021 → 2025

FY 202176.5%FY 202282.1%FY 202383.5%FY 202458.0%FY 202591.6%
76.5%91.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

33

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $7.6MBloch Stephen M · Director · $7.6MJun 24, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 17, 2026Filing
  • Insider sellInsider Sell $14.0MBloch Stephen M · Director · $14MJun 16, 2026Filing
  • Insider sellInsider Sell $1.7M · 10b5-1 PlanKrepp Sarah · Chief Human Resource Officer · $1.7MJun 15, 2026Filing
  • Insider sellInsider Sell $26.6MBloch Stephen M · Director · $26.6MJun 12, 2026Filing
  • Insider sellInsider Sell $14.3MBloch Stephen M · Director · $14.3MJun 10, 2026Filing
  • Insider sellInsider Sell $271K · 10b5-1 PlanKhindri Sanjeev · Chief Development Officer · $270.6KJun 10, 2026Filing
  • Insider sellInsider Sell $5.5MBloch Stephen M · Director · $5.5MJun 8, 2026Filing
  • Insider sellInsider Sell $12.8MManning Paul B · Director · $12.8MJun 8, 2026Filing
  • 8-K eventIndex InclusionJun 8, 2026Filing

Questions

Frequently asked questions

What is Liquidia Corporation's market cap?

Liquidia Corporation (LQDA) has a market capitalization of $5.5B.

What is LQDA's P/E ratio?

A meaningful P/E ratio is not available for LQDA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LQDA's price-to-book (P/B) ratio?

LQDA trades at 121.98 times book value per share.

Are insiders buying LQDA stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 33 sells at Liquidia Corporation in the last 90 days.

Same arena

Related companies in Biotechnology

CGON

CG Oncology, Inc. Common stock

$5.4B

CRSP

CRISPR Therapeutics AG

$5.4B

MIRM

Mirum Pharmaceuticals, Inc.

$5.1B

LEGN

Legend Biotech Corporation

$5B

TGTX

TG Therapeutics, Inc.

$5.9B

PTCT

PTC Therapeutics, Inc.

$6.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.